Welcome to CSNpharm! For Research Use Only!
Amyloid-β
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN13757 | Tramiprosate | 3687-18-1 | Tramiprosate targets soluble A to decrease amyloid plaque deposition and maintains A in a non-fibrillar form. |
| CSN23629 | HP-β-CD | 128446-35-5 | HP--CD is used to improve the solubility of lipophilic drugs It is also an inhibitor of amyloid- aggregation and A-induced toxicity |
| CSN19488 | Ginsenoside Re | 52286-59-6 | Ginsenoside Re is a panaxatriol saponin that has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. |
| CSN11056 | Frentizole | 26130-02-9 | Frentizole, an immunosuppressive drug, is an inhibitor of the A-ABAD interaction. |
| CSN11884 | EUK 134 | 81065-76-1 | EUK 134 a synthetic superoxide dismutase SODcatalase mimetic exhibits potent antioxidant activities and inhibits the formation of -amyloid and related amyloid fibril |
| CSN23259 | CRANAD 2 | 1193447-34-5 | CRANAD-2 is a difluoroboron-derivatized curcumins as near-infrared probe for in vivo detection of amyloid-beta deposits. Upon interacting with Abeta aggregates, CRANAD-2 undergoes a range of changes, which include a 70-fold fluorescence intensity increase, a 90 nm blue shift (from 805 to 715 nm), and a large increase in quantum yield. Moreover, this probe also shows a high affinity for Abeta aggregates (K(d) = 38.0 nM), a reasonable log P value (log P = 3), considerable stability in serum, and a weak interaction with albumin. After intravenous injection of this probe, 19-month-old Tg2576 mice exhibited significantly higher relative signal than that of the control mice over the same period of time. |
| CSN17400 | ARN2966 | 102212-26-0 | ARN2966 is a potent post-transcriptional modulator of APP expression and reduces expression of APP with resultant lower production of A |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
